Categories
HCRU

Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database

Kostikas K, Price D, Gutzwiller F S, Jones B I, Loefroth E, Clemens A, Fogel R, Jones R, Cao H. 18 Jul 2020

Categories
Epilepsy & Behaviour HCRU

Healthcare utilization and associated costs following initiation of perampanel in patients with epilepsy

Morgan C L, Varga S, Tsong W, Jenkins-Jones S, Holden S E. 28 May 2020

Categories
Diabetes Obesity & Metabolism HCRU

Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study

Holden S E, Morgan C L, Qiao Q, Jenkins-Jones S, Berni E R, Currie C J. 20 Feb 2017

Categories
HCRU

Healthcare Resource Utilisation Associated with Patients Treated with Either Exenatide Once Weekly or Basal Insulin: A Retrospective UK Database Analysis

Qiao Q, Morgan C L, Jenkins-Jones S, Berni E R, Currie C J and Holden S E. 01 Nov 2016

Categories
HCRU

Evaluation of The Cost Effectiveness of Rifaximin-α 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Sweden

Poole C D, Berni E R, Conway P, Radwan A, Currie C J. 01 Nov 2016

Categories
HCRU

Cost Effectiveness of Rifaximin-α 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In United Kingdom

Berni E R, Poole C D, Conway P, Radwan A, Currie C J. 01 Nov 2016

Categories
HCRU

Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe

Holden S E, Currie C J, Lennon M, Reynolds A V, Moots R J. 09 May 2016

Categories
HCRU Hepatic Encephalopathy

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α

Orr J G, Currie C J, Berni E R, Goel A, Moriarty K J, Sinha A, Gordon F, Dethier A, Dillon J F, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall R J, Hudson M. 07 Mar 2016

Categories
HCRU Value in Health

Evaluation of The Cost Effectiveness and Societal Impact of Rifaximin-α 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In The Netherlands

Whitehouse J T, Berni E R, Conway P, Radwan A, Henrar R, Currie C J. 01 Nov 2015

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

MEET OUR BRANDS

About HDS

  • Our company
  • Boilerplate copy

HUMAN DATA SCIENCE

Logo
  • The HDS Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

LIVINGSTONEIQ

Logo
  • The Livingstone Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

PREVALENCEUK

Logo
  • The PrevalenceUK Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

TYPOGRAPHY

  • Typestack

VOICE AND TONE

ICONS

  • Icon basics
  • Design considerations
  • Icon styles